DSIP
Also known as: Delta Sleep-Inducing Peptide · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
A nonapeptide originally isolated from the cerebral venous blood of sleeping rabbits, studied for sleep modulation, stress resilience, and indirect cognitive effects.
- Category
- Sleep & Recovery
- Half-life
- Short plasma half-life (under 10 min); functional effects persist longer
- Formula
- C₃₅H₄₈N₁₀O₁₅
- Weight
- 848.81 g/mol
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Section 1
Overview
Delta Sleep-Inducing Peptide (DSIP) is a small endogenous nonapeptide originally isolated in 1977 from the cerebral venous blood of rabbits during electrically induced delta-wave sleep. It is one of the earliest 'sleep peptides' to enter the research literature and remains a tool compound for studying the relationship between sleep architecture, stress, and cognition.
Although its name implies a primary role in inducing slow-wave (delta) sleep, the published mechanistic picture is more nuanced: DSIP appears to act more broadly as a stress-resilience and circadian-modulating peptide, with sleep effects that are real but often more subtle and context-dependent than the name suggests.
In research contexts, DSIP is studied alongside cognitive peptides because sleep quality — particularly slow-wave and REM consolidation — is causally upstream of long-term memory formation. Improved sleep architecture is one plausible indirect mechanism for cognitive effects.
Section 2
Discovery & History
- Isolated by Schoenenberger and Monnier in 1977 from cerebral venous blood of sleeping rabbits.
- Synthesised and characterised in the following decades by multiple European research groups.
- Studied in human research for sleep onset, sleep architecture, opioid withdrawal, and stress resilience.
- Remains a research peptide; no major clinical authorisations.
Section 3
Mechanism of Action
- 1Modulation of hypothalamic-pituitary-adrenal (HPA) axis activity, reducing stress-induced corticosterone elevations in research models.
- 2Influence on slow-wave sleep architecture in some — though not all — research conditions.
- 3Antioxidant effects in CNS tissue under stress conditions.
- 4Modulation of opioid peptide release, contributing to its studied role in opioid-withdrawal research.
- 5Possible direct effects on thalamocortical oscillatory activity — the system that generates delta waves.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Reduced stress-axis activation in animal stress paradigms.
- 2Improvements in subjective sleep quality in early human research.
- 3Studied utility in opioid withdrawal protocols (reduction of withdrawal-symptom severity).
- 4Indirect cognitive effects via improved sleep consolidation.
- 5Generally well-tolerated profile in published research.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / intranasal (research) | Microgram-range in research protocols | Typically once daily, often pre-sleep | Short courses |
Note: No standardised human protocol exists in Western clinical practice.
Section 6
Administration Routes
- Subcutaneous in most research.
- Intranasal in some protocols.
- Oral not viable due to peptide degradation.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in research at studied doses
- · Occasional mild headache or sleep-onset alteration
Rare / theoretical
- · Long-term safety data is limited
- · Possible interaction with HPA-axis-modulating medications
Contraindications
- · Not approved for human use
- · Pregnancy/lactation — no data
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the United Kingdom. Research chemical only.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
DSIP and slow-wave sleep architecture
Polysomnographic study reporting modest increases in slow-wave sleep duration in subjects receiving DSIP versus placebo.
DSIP in opioid withdrawal
Reduction in withdrawal-symptom severity scores in subjects receiving adjunct DSIP during opioid detoxification.
DSIP and HPA-axis stress response
Attenuation of stress-induced corticosterone elevations in rodent stress models.
Section 10
Frequently Asked Questions
Section 11
Sourcing for Laboratory Research
Sourcing DSIP for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain DSIP from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.